<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="64176">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02270450</url>
  </required_header>
  <id_info>
    <org_study_id>S1316</org_study_id>
    <secondary_id>U10CA037429</secondary_id>
    <secondary_id>1R01HS021491-01A1</secondary_id>
    <secondary_id>S1316</secondary_id>
    <secondary_id>NCI-2014-01497</secondary_id>
    <nct_id>NCT02270450</nct_id>
  </id_info>
  <brief_title>S1316, Surgery or Non-Surgical Management in Treating Patients With Intra-Abdominal Cancer and Bowel Obstruction</brief_title>
  <official_title>S1316, Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Agency for Healthcare Research and Quality (AHRQ)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This partially randomized clinical trial studies surgery or non-surgical management in
      treating patients with intra-abdominal cancer and bowel obstruction. Bowel obstruction is a
      common problem for advanced cancer patients and can negatively affect quality of life. It is
      not yet known whether surgery or non-surgical management is the best treatment option for
      bowel obstruction and can lead to better quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days alive and outside the hospital</measure>
    <time_frame>Within the first 91 days after enrollment</time_frame>
    <description>The primary analysis will pool data from both components using a multivariate linear regression model, including a parameter for study component. Factors considered likely to confound the association of treatment and outcome in the non-randomized component will be carefully modeled in the regression. Potential residual bias in the treatment group comparison from the non-randomized component will be assessed by estimating the interaction term between treatment group and study component (randomized vs. non-randomized).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ability to eat</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of nasogastric tube</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of intravenous hydration</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of solid food</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total self-reported energy intake</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of adverse events in patients with ascites</measure>
    <time_frame>Up to 1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of adverse events in patients with albumin &lt; 3.0</measure>
    <time_frame>Up to 1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of adverse events in patients with carcinomatosis evident in more than one quadrant of the abdomen</measure>
    <time_frame>Up to 1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Predictors of treatment in non-randomized arms</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>To explore whether there are clinical factors (ascites, albumin, carcinomatosis) that will predict better quality of life outcomes for patients with malignant bowel obstruction who receive surgical intervention as compared to non-surgical intervention.</description>
  </other_outcome>
  <other_outcome>
    <measure>Diversity of treatment in non-randomized arms (e.g., type of surgical procedure and medications)</measure>
    <time_frame>Up to 1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patterns of care over time in non-randomized arms, including frequency with which a patient initially selects one treatment approach is crossed over to the other strategy</measure>
    <time_frame>Up to 1 year</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Constipation, Impaction, and Bowel Obstruction</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I (randomized to surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo therapeutic conventional surgery (abdominal) as defined by the treating physician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (randomized to non-surgical management)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are offered gastrointestinal complications management/prevention (non-surgical management) as determined by the treating physician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (no randomization, surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo therapeutic conventional surgery (abdominal) as defined by the treating physician as in Arm I.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV (no randomization, non-surgical management)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are offered gastrointestinal complications management/prevention (non-surgical management) as determined by the treating physician as in Arm II.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Undergo abdominal surgery</description>
    <arm_group_label>Arm I (randomized to surgery)</arm_group_label>
    <arm_group_label>Arm III (no randomization, surgery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>gastrointestinal complications management/prevention</intervention_name>
    <description>Undergo non-surgical management</description>
    <arm_group_label>Arm II (randomized to non-surgical management)</arm_group_label>
    <arm_group_label>Arm IV (no randomization, non-surgical management)</arm_group_label>
    <other_name>complications management/prevention, gastrointestinal, management/prevention, gastrointestinal complications</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (randomized to surgery)</arm_group_label>
    <arm_group_label>Arm II (randomized to non-surgical management)</arm_group_label>
    <arm_group_label>Arm III (no randomization, surgery)</arm_group_label>
    <arm_group_label>Arm IV (no randomization, non-surgical management)</arm_group_label>
    <other_name>quality of life assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Patient must have malignant bowel obstruction (MBO) as evidenced by all of the
             following:

               -  Clinical evidence of a bowel obstruction (via history, physical, and
                  radiographic examination)

               -  Bowel obstruction below (distal to) ligament of Treitz

               -  Intra-abdominal primary cancer with incurable disease

          -  Patients must have malignant bowel obstruction due to an intra-abdominal primary
             cancer (i.e. stomach, small bowel [including duodenum], pancreas, colon, rectum,
             appendiceal, ovarian, uterine, cervical, kidney, bladder, prostate, gastrointestinal
             stromal tumor [GIST] [all sites], and sarcoma)

          -  Patient must be able to tolerate a major surgical procedure based on clinical
             evaluation, status of their cancer, and any other underlying medical problems

          -  A member of the patient's surgical team must indicate equipoise for the benefit of
             the surgical treatment for MBO; the surgeon must respond &quot;Yes&quot; to each of the
             following questions and sign the S1316 Surgical Equipoise Documentation form for the
             patient to be eligible:

               -  Is surgery for treatment of malignant bowel obstruction (MBO) being considered
                  for this patient?

               -  Do you have equipoise (If the treating team finds that an operation is required
                  [e.g., for acute abdomen], or they would not offer the patient an operation
                  [e.g., patient is too weak to tolerate surgery], then there is no equipoise)?

          -  Patients must not have signs of bowel perforation or &quot;acute&quot; abdomen as evidenced by
             free air on radiologic imaging or peritonitis on physical exam within 2 days prior to
             registration

          -  Patients must be registered to the study within 3 days after surgical consult for MBO
             and prior to any treatment (surgical or non-surgical) for MBO

          -  Patients must have Zubrod performance status of 0-2 within 7 days prior to
             registration

          -  Serum albumin must be planned to be collected after admission, but prior to treatment

          -  Patients must be able to complete the study questionnaires in English

          -  Patients or their legally authorized representative must be informed of the
             investigational nature of this study and must sign and give written informed consent
             in accordance with institutional and federal guidelines

          -  As a part of the Oncology Patient Enrollment Network (OPEN) registration process the
             treating institution's identity is provided in order to ensure that the current
             (within 365 days) date of institutional review board approval for this study has been
             entered in the system

          -  Patients must consent and provide both their contact information and that of their
             representative for a monthly 24-hour dietary recall phone call to be conducted by the
             Arizona Diet, Behavior and Quality of Life Assessment Lab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert S Krouse, M.D., F.A.C.S.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kimberly Kaberle</last_name>
    <phone>2106148808</phone>
    <phone_ext>1022</phone_ext>
    <email>kkaberle@swog.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dana Sparks, M.A.T.</last_name>
    <phone>2106148808</phone>
    <phone_ext>1004</phone_ext>
    <email>dsparks@swog.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Arizona Medical Center-University Campus</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentine N. Nfonsam</last_name>
      <phone>520-626-9008</phone>
    </contact>
    <investigator>
      <last_name>Valentine N. Nfonsam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan A. Laryea</last_name>
      <phone>501-686-8274</phone>
    </contact>
    <investigator>
      <last_name>Jonathan A. Laryea</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernest S. Han</last_name>
      <phone>800-826-4673</phone>
      <email>becomingapatient@coh.org</email>
    </contact>
    <investigator>
      <last_name>Ernest S. Han</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Summer B. Dewdney</last_name>
      <phone>312-942-5498</phone>
      <email>clinical_trials@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Summer B. Dewdney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mazin F. Al-kasspooles</last_name>
      <phone>913-945-7552</phone>
      <email>ctnursenav@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Mazin F. Al-kasspooles</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giles F. Whalen</last_name>
      <phone>508-856-6265</phone>
    </contact>
    <investigator>
      <last_name>Giles F. Whalen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillip E. Rodgers</last_name>
      <phone>800-865-1125</phone>
    </contact>
    <investigator>
      <last_name>Phillip E. Rodgers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Essentia Health Cancer Center</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bret E. Friday</last_name>
      <phone>888-203-7267</phone>
    </contact>
    <investigator>
      <last_name>Bret E. Friday</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southside Hospital</name>
      <address>
        <city>Bay Shore</city>
        <state>New York</state>
        <zip>11706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary B. Deutsch</last_name>
      <phone>516-734-8954</phone>
    </contact>
    <investigator>
      <last_name>Gary B. Deutsch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary B. Deutsch</last_name>
      <phone>516-734-8954</phone>
    </contact>
    <investigator>
      <last_name>Gary B. Deutsch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary B. Deutsch</last_name>
      <phone>516-734-8954</phone>
    </contact>
    <investigator>
      <last_name>Gary B. Deutsch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University/Herbert Irving Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William M. Burke</last_name>
      <phone>212-305-8615</phone>
    </contact>
    <investigator>
      <last_name>William M. Burke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angeles A. Secord</last_name>
      <phone>888-275-3853</phone>
    </contact>
    <investigator>
      <last_name>Angeles A. Secord</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camille Gunderson</last_name>
      <phone>405-271-8777</phone>
      <email>ou-clinical-trials@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Camille Gunderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas J. Miner</last_name>
      <phone>401-444-1488</phone>
    </contact>
    <investigator>
      <last_name>Thomas J. Miner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Whitney S. Graybill</last_name>
      <phone>843-792-9321</phone>
    </contact>
    <investigator>
      <last_name>Whitney S. Graybill</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Health Science Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremiah L. Deneve</last_name>
      <phone>901-448-3303</phone>
    </contact>
    <investigator>
      <last_name>Jeremiah L. Deneve</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey P. Lamont</last_name>
      <phone>800-422-9567</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey P. Lamont</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric J. Silberfein</last_name>
      <phone>713-798-1354</phone>
      <email>burton@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Eric J. Silberfein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian D. Badgwell</last_name>
      <phone>713-792-3245</phone>
    </contact>
    <investigator>
      <last_name>Brian D. Badgwell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Froedtert and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabian M. Johnston</last_name>
      <phone>414-805-5771</phone>
      <email>fjohnston@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Fabian M. Johnston</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 6, 2016</lastchanged_date>
  <firstreceived_date>October 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Intestinal Obstruction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
